Topical corticosteroids early in bacterial keratitis may improve vision

Article

Research from the University of California, San Francisco, found that adding topical corticosteroids two to three days after starting topical antibiotics for the treatment of bacterial keratitis is linked to improved vision, according to a study recently published in JAMA Ophthalmology.

San Francisco-Research from the University of California, San Francisco, found that adding topical corticosteroids two to three days after starting topical antibiotics for the treatment of bacterial keratitis is linked to improved vision, according to a study recently published in JAMA Ophthalmology

The study assessed the timing of the administration of corticosteroids in a subgroup analysis of the Steroids for Corneal Ulcers Trial (SCUT), a randomized, double-masked, placebo-controlled trial that overall found no effect of adding topical corticosteroids to topical moxifloxacin hydrochloride in bacterial keratitis.

The researchers assessed the effect of topical corticosteroids (vs. placebo) on three-month best spectacle-corrected visual acuity in patients who received the treatment or placebo earlier (two to three days after starting topical antibiotics) vs. later (four days or later after starting topical antibiotics). The group also analyzed subgroups of patients with non-Nocardia keratitis and those with no topical antibiotic use before enrollment.

The patients who received the topical corticosteroids earlier had approximately one-line better visual acuity at three months than those given the placebo. In patients who were given the topical corticosteroids later had one-line worse visual acuity at three months compared to those in the placebo group.

The study states, “There may be a benefit with adjunctive topical corticosteroids if application occurs earlier in the course of bacterial corneal ulcers.”

Recent Videos
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
Cecelia Koetting, OD, FAAO, DipABO, weighs in on patient assessments, staining pattern insights, and diagnostic tips for patients who may have dry eye disease.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, discusses keratoconus management, diagnosis, and other key insights at CRU 2025.
Cecelia Koetting, OD, FAAO, DipABO, details a talk she gave among optometrists and ophthalmologists at CRU 2025.
Alongside Rachelle Lin, OD, MS, FAAO; Nguyễn, MD, MSc, detailed what treatments are currently available for retinal vascular diseases, including neovascular age-related macular degeneration and diabetic retinopathy.
Dr Paul Karpecki discusses atropine formulation from Sydnexis following NDA acceptance by FDA
Ali Tafreshi sits down with Optometry Times to discuss Topcon's "Healthcare from the Eye" initiative.
Nora Lee Cothran, OD, FAAO, details a real-world study that found IOP-lowering benefits when switching patients with glaucoma to latanoprostene bunod treatment.
OptiLIFT in action: Dr. Julie McLaughlin's experience with the new device
© 2025 MJH Life Sciences

All rights reserved.